Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population

Haematologica

Volumn 91, Issue 12, 2006, Pages 1613-1620

  D'Angelo, Armando ^a,c   Ruotolo, Giacomo ^b   Garancini, Paola ^c   Sampietro, Francesca ^a   Mazzola, Giuseppina ^a   Calori, Giliola ^b,c  

^a Unita' Ricerca Trombosi   (Italy)

^b Unita' Ricerca Biologia Vascolare (GRGC)   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

C reactive protein; Coronary heart disease; Fibrinogen; Insulin; Lp(a); Stroke

Indexed keywords

FIBRINOGEN; LIPOPROTEIN A;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; ITALY; LIPOPROTEIN BLOOD LEVEL; MALE; MORTALITY; POPULATION RESEARCH; PROTEIN LOCALIZATION; SEX DIFFERENCE; STROKE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FIBRINOGEN; HEART DEFECTS, CONGENITAL; HUMANS; ITALY; LIPOPROTEIN(A); MALE; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; VASCULAR DISEASES;

EID: 33845962006     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ariyo AA, Thach C, Tracy R, for the Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease and mortality in the elderly. N Engl J Med 2003;349:2108-15.
2. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein (a): structural properties. J Biol Chem 1983;258:4582-9.
3. Scanu AM. Lp(a) lipoprotein - coping with heterogeneity. N Engl J Med 2003;349:2089-90.
4. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O. Apolipoprotein(a) isoforms and coronary heart disease in men. A nested case-control study. Atherosclerosis 1997;132:77-84.
5. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
6. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
7. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2004;11:9-17.
8. Hancock MA, Boffa MB, Marcovina SM, Nesheim MF, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003;278:23260-9.
9. Undas A, Stepien Z, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006;4:973-5.
10. Tsurupa G, Ho-Tin-Noe' B, Angles-Cano E, Medved L. Identification and characterization of novel lysine-independent apolipoprotein(a) binding sites in fibrin(ogen) αC-domains. J Biol Chem 2003;278:37154-9.
11. Lou XJ, Boonmark NW, Harrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998;95:12591-5.
12. Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbu E, Bozzetti AM, Boari L, Lazzari P, Gallus G. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 1995;38:306-13.
13. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, World Health Organization. 1999. p. 31-3.
14. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-202.
16. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Cem 1998;44:2301-6.
17. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
18. Wilhelmsen L, Svarrdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Toblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
19. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999;100:736-42.
20. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, et al. Bezafibrate Infarction Prevention Study Group. A prospective study of plasma fibrinogen levels and the risk or stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med 2001;111:457-63.
21. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002;105:2632-7.
22. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004;35:2300-5.
23. Zenker G, Koltringer F, Bone G, Niederkorn K, Pfeiffer K, Jurger G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17:942-5.
24. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993;24:965-9.
25. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390-7.
26. Rajecki M, Pajunen P, Jousilahti P, Rasi V, Vahtera E, Salomaa V. Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis study. Blood Coagul Fibrinolysis 2005;16:119-24.
27. Cremer P, Nagek D, Labrot B, Mahn H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-53.
28. Cantin B, Despres J-P, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec cardiovascular study). Am J Cardiol 2002;89:662-6.
29. Shai I, Rimm EB, Hankinson SE, Cannuscio C, Curhan G, Manson JE, et al. Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carried? Eur Heart J 2005;26:1633-9.
30. Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease a meta-analysis. Circulation 1998; 97:996-1001.
31. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality. The 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000;23:1097-102.
32. Folsom AR, Wu KK, Davies CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
33. Van der Bom JG, de Maat ML, Haverkate F, Hofman A, Kluft C, Grobbee DE. Elevated plasma fibrinogen: cause or consequence of cardiovascular diseased? Arterioscler Thromb Vasc Biol 1998;18:621-5.
34. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
35. Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgarde F. Influence
36. of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscl Thromb Vasc Biol 2001;21:452-8.
37. Sakkinen PA, Wahl P, Cushmann M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
38. Marques-Vidal PM, Mazoyer E, Bongard V, Gourdy P, Ruidavets J-B, Drouet L, et al. Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002;25:1371-7.
39. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
40. Mendall MA, Strachan DP, Rutland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
41. Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
42. Nilsson J. CRP - Marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527-8.
43. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004;103:1728-34.